GEN News Highlights: Jan 10, 2008

Scientists Uncover Novel Mechanism for Suppression of Oncogene

(Page 1 of 1)

    Researchers report that at least one tumor suppressor gene is in fact turned off by a noncoding RNA that is antisense to the sense gene. “This is the first time we’ve seen an antisense RNA silencing a tumor suppressor through the means of epigenetic changes,” according to Hengmi Cui, Ph.D., assistant professor of molecular medicine at Johns Hopkins University (JHU) and one of the authors of the paper.

    The scientists first surveyed computer databases for tumor suppressor genes with known neighboring antisense RNAs. They found antisense counterparts to 21 well-known tumor suppressor genes and decided to further study one of them, p15. This gene is reportedly deleted or silenced in several types of human cancer including melanomas, gliomas, lung and bladder carcinomas, and up to 60% of leukemias.

    The JHU team first analyzed leukemia cells for the presence of antisense p15. Of 16 patient samples, 11 showed an increase in antisense p15 and decreased p15. Further experiments showed that chemically turning on the antisense gene turned off the sense p15 gene.

    “Somehow, the presence of the antisense RNA leads to the formation of this tightening of the chromosome to make heterochromatin around the p15 gene, turning it off,” explains author Andrew Feinberg, M.D., professor of medicine, oncology, molecular biology, and genetics and director of the Epigenetics Center at JHU. “We’re now looking at other tumor suppressor genes to figure out how this happens and how general this phenomenon is.”

    Researchers from NCI were also involved in the study. The paper is published in the January 10 issue of Nature.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

BLOG biotech

Webinars

GEN Podcasts

Video Channel

New Products

Best of the Web

GEN Polls

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll